Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Connect Biopharma in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.23) per share for the year. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.20) per share. Leerink Partnrs also issued estimates for Connect Biopharma's FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.10) EPS and FY2028 earnings at ($0.49) EPS.
Connect Biopharma Stock Up 6.7 %
Shares of NASDAQ CNTB traded up $0.06 during midday trading on Monday, reaching $0.98. The stock had a trading volume of 1,431 shares, compared to its average volume of 16,711. Connect Biopharma has a twelve month low of $0.91 and a twelve month high of $2.66. The company's 50 day moving average price is $1.06 and its 200 day moving average price is $1.14.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Choreo LLC bought a new stake in shares of Connect Biopharma in the 4th quarter worth $204,000. BML Capital Management LLC lifted its holdings in Connect Biopharma by 2.4% during the third quarter. BML Capital Management LLC now owns 2,093,232 shares of the company's stock valued at $3,014,000 after purchasing an additional 49,984 shares during the last quarter. Catalina Capital Group LLC purchased a new stake in Connect Biopharma during the fourth quarter valued at about $66,000. Finally, Callan Capital LLC lifted its holdings in Connect Biopharma by 91.3% during the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company's stock valued at $110,000 after purchasing an additional 38,177 shares during the last quarter. Institutional investors and hedge funds own 58.72% of the company's stock.
Connect Biopharma Company Profile
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Featured Stories
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
